Other
Research and development expense
AbbVie Research and development expense increased by 19.6% to $2.47B in Q1 2026 compared to the prior quarter.
Analysis
StatementIncome Statement
SectionOther
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026May 8, 2026
How to read this metric
Higher spending typically signals a commitment to long-term innovation and future product pipelines, while significant cuts may signal a shift toward short-term profitability.
Detailed definition
This metric captures the investment in creating new products, improving existing technologies, and advancing internal ca...
Peer comparison
Standard metric for technology and hardware firms; highly comparable to R&D spending at peers.
Metric ID:
other_research_and_development_expense_excluding_acquire_88a3cdHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $2.07B | $2.47B |
| QoQ Change | — | +19.6% |
| YoY Change | — | +19.6% |
Range$2.07B – $2.47B
Avg YoY Growth+19.6%
Median YoY Growth+19.6%
Research and development expense at Other Companies
Frequently Asked Questions
- What is AbbVie's research and development expense?
- AbbVie (ABBV) reported research and development expense of $2.47B in Q1 2026.
- What does research and development expense mean?
- Spending on innovation and product development.